MDF is pleased to announce the launch of a new program, MDF DM Days. These special one-day free events will be held in three locations across the U.S. in 2017, bringing together clinicians, researchers and MDF community members to share information and resources.
Even though Donna Boulmay spent a career as a nurse before retiring, she lived most of her adult life in the midst of a medical mystery that had shaped much of her family’s existence. That changed shortly after her grandson Jackson turned five years old.
The currently active NHLBI initiative, NHLBI Clinical Trial Pilot Studies (R34), provides funding for up to 3 years/$450,000 total direct costs to support studies sufficient to the design of interventional clinical trials in their mission.
Epigenetic modifications upstream of an expanded DMPK allele may underlie the maternal bias in the inheritance of CDM.
A multi-center study suggests serum cardiac troponin-1 levels predict risks of left ventricular dysfunction in DM1 patients.
In March, Republican Members of the U.S. House of Representatives’ Committee on Ways and Means and the U.S. House Committee on Energy and Commerce introduced legislation, entitled the American Health Care Act (AHCA), that would repeal and/or replace major parts of the Affordable Care Act (ACA).
A potentially revolutionary technology may allow development of a drug for DM that can correct a patient’s DNA by selectively removing the expanded CTG and CCTG repeats in DM1 and DM2, respectively.